Jim Segermark administrerende direktør i situ biologiske situ biologiske er en ny ... Registrer deg gratis for arrangementet situ biologiske & Manhattan Street ... biologiske – Matrix BioHydrogel™ & AnestaGel™ Jim Segermark, administrerende direktør situ ...
RodTurners blogg Når situ biologiske, Inc. åpnet Reg A ... it for den høyere risikodelen av deres portefølje,» forklarte han. situ biologiske ... situgjennomsnittlig ikke-IRA-investering har vært rundt $12,000 XNUMX, sa han, sammenlignet med ...
Invester i Anestagel. En ny, opioidfri smertestillende middel.
fag." situ biologiske' AnestaGel™, non-opioid pain relief drug based ... Qualification of situ Biologisk’s RegA+ Offering, numerous previous investors ... issued, $20 Bill market. situ is now accepting reservations via ...
of an annual $90 billion market opportunity. situ biologiske' fokus ... av aksjer er nesten utsolgt. situ biologiske is accepting a limited amount of investments at $6.90 per share. *Due to the demand for situ biologiske’ stock, ...
Gjør en investering i IdentifySensors Biologics.
7:00PM Networking EXPERTS: Jim Segermark | Host; CEO, situ biologiske ... Om situ biologiske situ biologiske is an emerging biotech company, ... Segermark, CEO of situ biologiske 1-651-338-4801 | [e-postbeskyttet] ...
their Offering Circular HERE. situ biologiske situ biologiske is an emerging ... overdose. situ is focused on providing a solution to these problems. situ har ...
View our Offering Circular HERE. situ biologiske- AnestaGel™ situ biologiske is an emerging biotech company focusing on the development of AnestaGel™, a long-acting non-opiate painkiller. insitu has raised $2.57 million ...
is in the early stages of an annual $90 billion market opportunity. situ biologiske ... UT INSITU BIOLOGIKK HERE. View their Offering Circular HERE ... to be approved by the Swiss Regulators. CHECK OUT TALKETH HERE. situ Bi ...
